Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express03-16

Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes:

• Reviewing and approving the consolidated financial results for the year ended 31 December 2025.

• Considering publication of the audited annual results.

• Evaluating the declaration of a final dividend, if any.

The board currently consists of nine directors: three executive directors (Dr. Bo Chen, Dr. Changyu Wang, Dr. Gang Xu), three non-executive directors (Mr. Qi Chen, Dr. Min Chuan Wang, Mr. Yilun Liu) and three independent non-executive directors (Prof. Xiao-Fan Wang, Prof. Yang Ke, Mr. Cheuk Kin Stephen Law).

The announcement was authorized by Chairman Dr. Bo Chen and released in Hong Kong on 16 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136749979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136749979","market":"hk","top_or_hot":-1,"title":"Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated financial results for the year ended 31 December 2025.</p>\n<p>• Considering publication of the audited annual results.</p>\n<p>• Evaluating the declaration of a final dividend, if any.</p>\n<p>The board currently consists of nine directors: three executive directors (Dr. Bo Chen, Dr. Changyu Wang, Dr. Gang Xu), three non-executive directors (Mr. Qi Chen, Dr. Min Chuan Wang, Mr. Yilun Liu) and three independent non-executive directors (Prof. Xiao-Fan Wang, Prof. Yang Ke, Mr. Cheuk Kin Stephen Law).</p>\n<p>The announcement was authorized by Chairman Dr. Bo Chen and released in Hong Kong on 16 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 17:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated financial results for the year ended 31 December 2025.</p>\n<p>• Considering publication of the audited annual results.</p>\n<p>• Evaluating the declaration of a final dividend, if any.</p>\n<p>The board currently consists of nine directors: three executive directors (Dr. Bo Chen, Dr. Changyu Wang, Dr. Gang Xu), three non-executive directors (Mr. Qi Chen, Dr. Min Chuan Wang, Mr. Yilun Liu) and three independent non-executive directors (Prof. Xiao-Fan Wang, Prof. Yang Ke, Mr. Cheuk Kin Stephen Law).</p>\n<p>The announcement was authorized by Chairman Dr. Bo Chen and released in Hong Kong on 16 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1136749979","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136749979","pubTimestamp":1773652899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes: • Reviewing and approving the consolidated financial results for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"康康生物科技(02162)定于2026年3月26日召开董事会，批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes:\n• Reviewing and approving the consolidated financial results for the year ended 31 December 2025.\n• Considering publication of the audited annual results.\n• Evaluating the declaration of a final dividend, if any.\nThe board currently consists of nine directors: three executive directors (Dr. Bo Chen, Dr. Changyu Wang, Dr. Gang Xu), three non-executive directors (Mr. Qi Chen, Dr. Min Chuan Wang, Mr. Yilun Liu) and three independent non-executive directors (Prof. Xiao-Fan Wang, Prof. Yang Ke, Mr. Cheuk Kin Stephen Law).\nThe announcement was authorized by Chairman Dr. Bo Chen and released in Hong Kong on 16 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136749979","isCrawlerRequest":true}